In the US, several blood tests for the early detection of Alzheimer's are now available, enabling faster and more precise diagnosis. These tests can provide direct indications of the accumulation of amyloid proteins in the brain – an important biomarker for Alzheimer's.
Key Tests at a Glance
– PrecivityAD™: Available since 2020, costs about $1,200, and measures the ratio of different amyloid-beta proteins as well as genetic risk factors
– AD-Detect: Developed by Quest Diagnostics, costs $500, and is covered by some insurance plans
– PrecivityAD2™: Latest version, which also measures tau proteins
– ALZpath Dx: First test to measure pTau217, available since early 2024
Experts Urge Caution
Despite the promising developments, experts warn against premature widespread use:
– The data so far comes mainly from clinical studies with homogeneous participant groups
– Comorbidities can lead to false results
– The tests should only be used in conjunction with cognitive assessments
– Detailed consultation by trained physicians is required
The Alzheimer's Association currently recommends the use of blood tests only in specialized memory clinics and for research purposes. Further studies, especially with more diverse patient groups, are still needed.
*As of: February 10, 2025*
Sources:
[1] https://www.brightfocus.org/resource/alzheimers-blood-tests-how-do-they-work-and-should-you-request-one/
